Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC

Low Contrast Agent and Radiation Dose Protocol Liver CT With Deep-learning-based Contrast Boosting Model in Patients at High Risk for HCC: Prospective, Randomized, Single Blinded - Preliminary Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04722120

Enrollment

Registered

2021-01-25

Start date

2016-06-01

Completion date

2021-01-01

Last updated

2022-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

Brief summary

The purpose of this study is to investigate the image quality and clinical feasibility of double low-dose liver computed tomography using a deep-learning-based iodine contrast boosting algorithm in participants at high risk for hepatocellular carcinoma.

Detailed description

The purpose of this study is to investigate the image quality (CNR, subjective inage quality, vessel and lesion conspicuity) and clinical feasibility (rate of lesion detection) of double low-dose liver computed tomography using a deep-learning-based iodine contrast boosting algorithm in participants at high risk for hepatocellular carcinoma.

Interventions

RADIATIONLow radiation dose CT

Underwent liver CT with 30% lower radiation dose

RADIATIONConventional CT (radiation)

Underwent liver CT without change of radiation.

DRUGLow contrast dose CT

Underwent liver CT 20% lower dose contrast media.

DRUGConventional CT (contrast agent)

Underwent liver CT without change of contrast media doses.

OTHERDeep-learning based contrast boosting algorithms

Applied deep-learning based contrast boosting algorithms on acquired CT images

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Caregiver)

Masking description

Participants, investigators, and outcome assessors were all masked to the allocation

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Liver cirrhosis * Tumor marker (aFP, PIVKA) elevation * Nodular lesion on USG * Received RFA for HCC

Exclusion criteria

* hypersensitivity at iodine * GFR under 30 * BMI over 30 * Nursing or pregnant women * enrolled the other study

Design outcomes

Primary

Measure	Time frame	Description
Detection rate of solid focal lesion in liver	12 months after last patient's image work up	diagnostic performance
Quantitative image quality analysis	Immediate after study enrollement	Contrast-to-Noise

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026